Transcription of Public Assessment Report Decentralised Procedure
{{id}} {{{paragraph}}}
Example: dental hygienist
Public Assessment Report Decentralised Procedure
Public Assessment Report Decentralised Procedure LIOTHYRONINE SODIUM 20 MICROGRAM TABLETS (liothyronine sodium) Procedure No: UK/H/6516/001/DC UK Licence No: PL 00289/2116 Teva UK Limited PAR Liothyronine Sodium 20 microgram Tablets UK/H/6516/001/DC 2 LAY SUMMARY Liothyronine Sodium 20 microgram Tablets (liothyronine sodium) This is a summary of the Public Assessment Report (PAR) for Liothyronine Sodium 20 microgram Tablets (PL 00289/2116; UK/H/6516/001/DC). It explains how Liothyronine Sodium 20 microgram Tablets were assessed and their authorisation recommended as well as their conditions of use. It is not intended to provide practical advice on how to use Liothyronine Sodium 20 microgram Tablets. For practical information about using Liothyronine Sodium 20 microgram Tablets, patients should read the package leaflet or contact their doctor or pharmacist. This medicinal product will be referred to as Liothyronine Sodium Tablets for the remainder of this summary, for ease of reading.
PAR Liothyronine Sodium 20 microgram Tablets UK/H/6516/001/DC 2 LAY SUMMARY Liothyronine Sodium 20 microgram Tablets (liothyronine sodium) This is a summary of the Public Assessment Report (PAR) for Liothyronine Sodium 20 microgram
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: